FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2801472507> ?p ?o ?g. }

• W2801472507 endingPage "2199" @default.
• W2801472507 startingPage "2191" @default.
• W2801472507 abstract "Secukinumab, a fully human monoclonal antibody that selectively neutralizes interleukin 17A, has demonstrated strong and sustained efficacy in adults with moderate to severe psoriasis in clinical trials.This analysis compared the cost per responder of secukinumab as first biologic treatment of moderate to severe psoriasis, with adalimumab, infliximab, etanercept and ustekinumab in Germany.A 52-week decision-tree model was developed. Response to treatment was assessed based on the likelihood of achieving a predefined Psoriasis Area and Severity Index (PASI) response to separate the cohort into responders (PASI ≥75), partial responders (PASI 50 to 74) and non-responders (PASI <50). Responders at week 16 continued initial treatment, whereas partial responders and non-responders were switched to standard of care, which included methotrexate, cyclosporine, phototherapy and topical corticosteroids. Sustained response was defined as 16-week response maintained at week 52. A German healthcare system perspective was adopted. Clinical efficacy data were obtained from a mixed-treatment comparison; 2016 resource unit costs from national sources; and adverse events and discontinuation rates from the literature. We calculated cost per PASI 90 responder over week 16 and week 52, as well as cost per sustained responder between weeks 16 and 52.Secukinumab had the lowest cost per PASI 90 responder over 16 weeks (€18 026) compared with ustekinumab (€18 080), adalimumab (€23 499), infliximab (€29 599) and etanercept (€34 037). Over 52 weeks, costs per PASI 90 responder ranged from €42 409 (secukinumab) to €70 363 (etanercept). Likewise, secukinumab had the lowest cost per sustained 52-week PASI 90 responder (€22 690) compared with other biologic treatments. Sensitivity analyses, excluding patient copayments, showed similar results.First biologic treatment with secukinumab for moderate to severe psoriasis is cost-effective, with lowest cost per responder compared with other biologic treatments in Germany." @default.
• W2801472507 created "2018-05-17" @default.
• W2801472507 creator A5006954748 @default.
• W2801472507 creator A5012360460 @default.
• W2801472507 creator A5013763025 @default.
• W2801472507 creator A5036641783 @default.
• W2801472507 creator A5050516844 @default.
• W2801472507 creator A5079373093 @default.
• W2801472507 date "2018-06-27" @default.
• W2801472507 modified "2023-10-01" @default.
• W2801472507 title "Cost-effectiveness of secukinumab as first biologic treatment, compared with other biologics, for moderate to severe psoriasis in Germany" @default.
• W2801472507 cites W1900531238 @default.
• W2801472507 cites W1957267795 @default.
• W2801472507 cites W1973354423 @default.
• W2801472507 cites W1994127723 @default.
• W2801472507 cites W2016388800 @default.
• W2801472507 cites W2023333262 @default.
• W2801472507 cites W2029550355 @default.
• W2801472507 cites W2045676810 @default.
• W2801472507 cites W2046549669 @default.
• W2801472507 cites W2067327580 @default.
• W2801472507 cites W2080390872 @default.
• W2801472507 cites W2087096065 @default.
• W2801472507 cites W2097170399 @default.
• W2801472507 cites W2101806086 @default.
• W2801472507 cites W2103750969 @default.
• W2801472507 cites W2111608103 @default.
• W2801472507 cites W2134233465 @default.
• W2801472507 cites W2180295302 @default.
• W2801472507 cites W2238074512 @default.
• W2801472507 cites W2505074882 @default.
• W2801472507 cites W2521243079 @default.
• W2801472507 cites W2545668261 @default.
• W2801472507 cites W2586220284 @default.
• W2801472507 cites W2621777477 @default.
• W2801472507 cites W2740044328 @default.
• W2801472507 cites W2745179561 @default.
• W2801472507 cites W2751504203 @default.
• W2801472507 cites W2756408557 @default.
• W2801472507 cites W4211077900 @default.
• W2801472507 doi "https://doi.org/10.1111/jdv.15047" @default.
• W2801472507 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/29729105" @default.
• W2801472507 hasPublicationYear "2018" @default.
• W2801472507 type Work @default.
• W2801472507 sameAs 2801472507 @default.
• W2801472507 citedByCount "18" @default.
• W2801472507 countsByYear W28014725072018 @default.
• W2801472507 countsByYear W28014725072019 @default.
• W2801472507 countsByYear W28014725072020 @default.
• W2801472507 countsByYear W28014725072021 @default.
• W2801472507 countsByYear W28014725072022 @default.
• W2801472507 countsByYear W28014725072023 @default.
• W2801472507 crossrefType "journal-article" @default.
• W2801472507 hasAuthorship W2801472507A5006954748 @default.
• W2801472507 hasAuthorship W2801472507A5012360460 @default.
• W2801472507 hasAuthorship W2801472507A5013763025 @default.
• W2801472507 hasAuthorship W2801472507A5036641783 @default.
• W2801472507 hasAuthorship W2801472507A5050516844 @default.
• W2801472507 hasAuthorship W2801472507A5079373093 @default.
• W2801472507 hasConcept C126322002 @default.
• W2801472507 hasConcept C16005928 @default.
• W2801472507 hasConcept C17991360 @default.
• W2801472507 hasConcept C197934379 @default.
• W2801472507 hasConcept C2776260265 @default.
• W2801472507 hasConcept C2777011040 @default.
• W2801472507 hasConcept C2777138892 @default.
• W2801472507 hasConcept C2777226972 @default.
• W2801472507 hasConcept C2777575956 @default.
• W2801472507 hasConcept C2778715236 @default.
• W2801472507 hasConcept C2778975655 @default.
• W2801472507 hasConcept C2779786854 @default.
• W2801472507 hasConcept C2780132546 @default.
• W2801472507 hasConcept C2780564577 @default.
• W2801472507 hasConcept C71924100 @default.
• W2801472507 hasConceptScore W2801472507C126322002 @default.
• W2801472507 hasConceptScore W2801472507C16005928 @default.
• W2801472507 hasConceptScore W2801472507C17991360 @default.
• W2801472507 hasConceptScore W2801472507C197934379 @default.
• W2801472507 hasConceptScore W2801472507C2776260265 @default.
• W2801472507 hasConceptScore W2801472507C2777011040 @default.
• W2801472507 hasConceptScore W2801472507C2777138892 @default.
• W2801472507 hasConceptScore W2801472507C2777226972 @default.
• W2801472507 hasConceptScore W2801472507C2777575956 @default.
• W2801472507 hasConceptScore W2801472507C2778715236 @default.
• W2801472507 hasConceptScore W2801472507C2778975655 @default.
• W2801472507 hasConceptScore W2801472507C2779786854 @default.
• W2801472507 hasConceptScore W2801472507C2780132546 @default.
• W2801472507 hasConceptScore W2801472507C2780564577 @default.
• W2801472507 hasConceptScore W2801472507C71924100 @default.
• W2801472507 hasIssue "12" @default.
• W2801472507 hasLocation W28014725071 @default.
• W2801472507 hasLocation W28014725072 @default.
• W2801472507 hasOpenAccess W2801472507 @default.
• W2801472507 hasPrimaryLocation W28014725071 @default.
• W2801472507 hasRelatedWork W1485937383 @default.
• W2801472507 hasRelatedWork W1920699911 @default.
• W2801472507 hasRelatedWork W1969991375 @default.
• W2801472507 hasRelatedWork W1984399057 @default.

• next